Complete scanning of the CDK4 gene by denaturing gradient gel electrophoresis: A novel missense mutation but low overall frequency of mutations in sporadic metastatic malignant melanoma

International Journal of Cancer

Volumn 72, Issue 5, 1997, Pages 780-783

  Guldberg, Per ^a   Kirkin, Alexei F ^a   Grønbæk, Kirsten ^a,b   Thor Straten, Per ^a   Ahrenkiel, Vibeke ^a   Zeuthen, Jesper ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; GENE PRODUCT;

ALLELE; ARTICLE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; MISSENSE MUTATION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTO ONCOGENE;

ASPARAGINE; BIOPSY; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; DNA MUTATIONAL ANALYSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; SERINE; TUMOR CELLS, CULTURED;

EID: 0030838776     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970904)72:5<780::AID-IJC13>3.0.CO;2-D     Document Type: Article

References (18)

1. BARTKOVA, J., LUKAS, J., GULDBERG, P., ALSNER, J., KIRKIN, A.F., ZEUTHEN, J. and BARTEK, J., The p16-cyclin D/Cdk4-pRB pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res., 56, 5475-5483 (1996).
2. BATES, S., BONETTA, L., MACALLAN, D., PARRY, D., HOLDER, A., DICKSON, C. and PETERS, G., CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene, 9, 71-79 (1994).
3. DRACOPOLI, N.C. and FOUNTAIN, J.W., CDKN2 mutations in melanoma. Cancer Surv., 26, 115-132 (1996).
4. FISCHER, U., MELTZER, P. and MEESE, E., Twelve amplified and expressed genes localized in a single domain in glioma. Hum. Genet., 98, 625-628 (1996).
5. FITZGERALD, M.G., HARKIN, D.P., SILVA ARRIETA, S., MACDONALD, D.J., LUCCHINA, L.C., UNSAL, H., O'NEILL, E., KOH, J., FINKELSTEIN, D.M., ISSELBACHER, K.J., SOBER, A.J. and HABER, D.A., Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. nat. Acad. Sci (Wash.), 93, 8541-8545 (1996).
6. GULDBERG, P., NEDERGAARD, T., NIELSEN, H.J., OLSEN, A.C., AHRENKIEL, V. and ZEUTHEN, J., Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum. Mutation, 9, 348-355 (1997).
7. HALL, M. and PETERS, G., Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res., 68, 67-108 (1996).
8. HE, J., ALLEN, J.R., COLLINS, V.P., ALLALUNIS TURNER, M.J., GODBOUT, R., DAY, R.S. and JAMES, C.D., CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54, 5804-5807 (1994).
9. KIRKIN, A.F., PETERSEN, T.R., OLSEN, A.C., LI, L., THOR STRATEN, P. and ZEUTHEN, J., Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol. Immunother., 41, 71-81 (1995).
10. LERMAN, L.S. and SILVERSTEIN, K., Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol., 155, 482-501 (1987).
11. 1 control. Cancer Res., 55, 4818-4823 (1995).
12. MAELANDSMO, G.M., FLORENES, V.A., HOVIG, E., OYJORD, T., ENGEBRAATEN, O., HOLM, R., BØRRESEN, A.L. and FODSTAD, Ø., Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Brit. J. Cancer, 73, 909-916 (1996).
13. RYCHLIK, W. and RHOADS, R.E., A computer program for choosing optimal oligonucleotide primers for filter hybridization, sequencing and in vitro amplification. Nucleic Acids Res., 17, 8543-8551 (1989).
14. SAXENA, A., ROBERTSON, J.T. and ALI, I.U., Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas. Oncogene, 13, 661-664 (1996).
15. THOR STRATEN, P., KIRKIN, A.F., SEREMET, T. and ZEUTHEN, J., Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. Int. J. Cancer. 70, 582-586 (1997).
16. UEKI, K., ONO, Y., HENSON, J.W., EFIRD, J.T., VON DEIMLING, A. and LOUIS, D.N., CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56, 150-153 (1996).
17. WÖLFEL, T., HAUER, M., SCHNEIDER, J., SERRANO, M., WÖLFEL, C., KLEHMAN-HIEB, E., DE PLAEN, E., HANKELN, T., MEYER ZUM BÜSCHENFELDE, K.-H. and BEACH, D., A p16INK4a-insensitive CDK4 mutant targeted by cytologic T lymphocytes in a human melanoma. Science, 269, 1281-1284 (1995)
18. Zuo, L., WEGER, J., YANG, Q., GOLDSTEIN, A.M., TUCKER, M.A., WALKER, G.J., HAYWARD, N. and DRACOPOLI, N.C., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nature (Genet.), 12, 97-99 (1996).